Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 (vol 27, pg 5236, 2021)

被引：5
|
作者：
Saleh, Mansoor N.
Patel, Manish R.
Bauer, Todd M.
Goel, Sanjay
Falchook, Gerald S.
Shapiro, Geoffrey I.
Chung, Ki Y.
Infante, Jeffrey R.
Conry, Robert M.
Rabinowits, Guilherme
Hong, David S.
Wang, Judy S.
Steidl, Ulrich
Walensky, Loren D.
Naik, Gurudatta
Guerlavais, Vincent
Vukovic, Vojislav
Annis, D. Allen
Aivado, Manuel
Meric-Bernstam, Funda
机构：
来源：
CLINICAL CANCER RESEARCH | 2022年 / 28卷 / 02期
关键词：
D O I：
10.1158/1078-0432.CCR-21-4241
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：429 / 429
页数：1
相关论文
共 21 条
  • [1] Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53
    Saleh, Mansoor N.
    Patel, Manish R.
    Bauer, Todd M.
    Goel, Sanjay
    Falchook, Gerald S.
    Shapiro, Geoffrey, I
    Chung, Ki Y.
    Infante, Jeffrey R.
    Conry, Robert M.
    Rabinowits, Guilherme
    Hong, David S.
    Wang, Judy S.
    Steidl, Ulrich
    Naik, Gurudatta
    Guerlavais, Vincent
    Vukovic, Vojislav
    Annis, D. Allen
    Aivado, Manuel
    Meric-Bernstam, Funda
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (19) : 5236 - 5247
  • [2] First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
    Pairawan, Seyed
    Zhao, Ming
    Yuca, Erkan
    Annis, Allen
    Evans, Kurt
    Sutton, David
    Carvajal, Luis
    Ren, Jian-Guo
    Santiago, Solimar
    Guerlavais, Vincent
    Akcakanat, Argun
    Tapia, Coya
    Yang, Fei
    Bose, Priya Subash Chandra
    Zheng, Xiaofeng
    Dumbrava, Ecaterina Ileana
    Aivado, Manuel
    Meric-Bernstam, Funda
    [J]. BREAST CANCER RESEARCH, 2021, 23 (01)
  • [3] First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models
    Seyed Pairawan
    Ming Zhao
    Erkan Yuca
    Allen Annis
    Kurt Evans
    David Sutton
    Luis Carvajal
    Jian-Guo Ren
    Solimar Santiago
    Vincent Guerlavais
    Argun Akcakanat
    Coya Tapia
    Fei Yang
    Priya Subash Chandra Bose
    Xiaofeng Zheng
    Ecaterina Ileana Dumbrava
    Manuel Aivado
    Funda Meric-Bernstam
    [J]. Breast Cancer Research, 23
  • [4] The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, enhances antitumor efficacy of paclitaxel and Nab-paclitaxel in TP53 wild-type MCF-7 breast cancer models
    Pairawan, S. S.
    Yuca, E.
    Evans, K.
    Annis, A.
    Narasimhan, N.
    Sutton, D.
    Carvajal, L. A.
    Ren, J-G
    Santiago, S.
    Guerlavais, V.
    Akcakanat, A.
    Tapia, C.
    Dumbrava, E. E. Illeana
    Aivado, M.
    Meric-Bernstam, F.
    [J]. CANCER RESEARCH, 2019, 79 (04)
  • [5] Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type
    Sallman, David A.
    Borate, Uma
    Cull, Elizabeth H.
    Donnellan, William B.
    Komrokji, Rami S.
    Steidl, Ulrich G.
    Corvez, Maria M.
    Payton, Marie
    Annis, D. Allen
    Pinchasik, Dawn
    Aivado, Manuel
    Verma, Amit
    [J]. BLOOD, 2018, 132
  • [6] A Phase I multicenter trial of the dual MDM2/MDMX inhibitor ALRN-6924 in children and young adults with relapsed/refractory pediatric cancers
    Shulman, David S.
    Vo, Kieuhoa T.
    Fox, Elizabeth
    Muscal, Jodi A.
    Walensky, Loren D.
    Pikman, Yana
    Stegmaier, Kimberly
    Church, Alanna
    Crompton, Brian D.
    Place, Andrew E.
    Chi, Susan N.
    O'Neill, Allison F.
    Kamihara, Junne
    Ezrre, Suzanne
    Carlowicz, Cecilia
    Pinchasik, Dawn
    Al-Sayegh, Hasan
    Ma, Clement
    London, Wendy B.
    DuBois, Steven G.
    [J]. CANCER RESEARCH, 2019, 79 (13)
  • [7] In Vitro andpre-Clinical In Vivo evidence Support MDMX/MDM2 As Common Vulnerabilities across TP53 -Wild-Type T-Cell Lymphomas That Are Targetable with the α-Helical p53 Stapled Peptide Alrn-6924
    Koch, Raphael
    Christie, Amanda L.
    Yoshida, Noriaki
    Ng, Samuel Y.
    Shigemori, Kay
    Morrow, Sara N.
    Van Scoyk, Alexandria
    Horwitz, Steven M.
    Jacobsen, Eric
    Santiago, Solimar
    Ren, Jian-Guo
    Guerlavais, Vincent
    Annis, D. Allan
    Aivado, Manuel A.
    Weinstock, David M.
    [J]. BLOOD, 2017, 130
  • [8] Phase 2a study of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of wild-type TP53 in patients with peripheral t-cell lymphoma
    Payton, M.
    Pinchasik, D.
    Mehta, A.
    Goel, S.
    Zain, J. M.
    Sokol, L.
    Jacobsen, E.
    Patel, M. R.
    Horwitz, S. M.
    Meric-Bernstam, F.
    Shustov, A.
    Weinstock, D.
    Aivado, M.
    Annis, D. A.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [9] Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas.
    Meric-Bernstam, Funda
    Saleh, Mansoor N.
    Infante, Jeffrey R.
    Goel, Sanjay
    Falchook, Gerald Steven
    Shapiro, Geoffrey
    Chung, Ki Y.
    Conry, Robert Martin
    Hong, David S.
    Wang, Judy Sing-Zan
    Steidl, Ulrich
    Walensky, Loren D.
    Guerlavais, Vincent
    Payton, Marie
    Annis, D. Allen
    Aivado, Manuel
    Patel, Manish R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Phase 1 study of MDM2 antagonist ASTX295 in patients with solid tumors with wild-type TP53
    Dumbrava, Ecaterina E.
    Iwamoto, Fabio M.
    Agulnik, Mark
    Milhem, Mohammed
    Tolcher, Anthony W.
    Chugh, Rashmi
    Demeure, Michael J.
    Mita, Alain
    Demel, Kurt
    Diamond, Mark
    Mirakhur, Beloo
    Wilson, Laksmi
    Oganesian, Aram
    Chan, Danna
    Keer, Harold N.
    Taylor, Jason
    Sims, Martin J.
    Biondo, Andrea
    Jueliger, Simone
    Spira, Alexander
    [J]. CANCER RESEARCH, 2024, 84 (07)
123